Item 7.01 Regulation FD Disclosure.

Pursuant to Regulation FD, PLx Pharma Inc. (the "Company") hereby furnishes the Corporate Presentation that Natasha Giordano, the Company's President and Chief Executive Officer, and Rita O'Connor, the Company's Chief Financial Officer, will present to investors on or after March 15, 2022. The Corporate Presentation is attached hereto as Exhibit 99.1 and will be available on the Company's website under the Investor Relations tab.

The information furnished by the Company pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.





 (d) Exhibits




  Exhibit No. Description

99.1 PLx Pharma Inc. March 2022 Corporate Presentation.

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded

within the Inline XBRL document).

© Edgar Online, source Glimpses